Clinical Efficacy of Omadacycline

Omadacycline is noninferior to comparators in the treatment of skin and soft-tissue infections and community-acquired pneumonia.

Omadacycline is a new-generation tetracycline approved by the FDA in the fall of 2018 (NEJM JW Infect Dis Dec 2018 and Nuzyra (omadacycline) prescribing information) for treatment of acute bacterial skin and soft-tissue infections (ABSSIs) and community-acquired bacterial pneumonia (CABP). The results of two manufacturer-funded, phase 3 clinical trials supporting the compound's approval have now been published.

Stets and colleagues enrolled 774 adult patients with CABP in a randomized, controlled trial comparing 7 to 14 days of omadacycline (100 mg intravenously every 12 hours for 1 day, then 100 mg intravenously daily, or for at least 3 days followed by 300 mg orally daily) with 7 to 14 days of moxifloxacin (400 mg intravenously daily, or f…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Clinical Efficacy of Omadacycline

Topics

Reviewing Author